<DOC>
	<DOC>NCT01981031</DOC>
	<brief_summary>BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin Lispro. The aim of this trial is to assess the efficacy and safety of BioChaperone® Combo in subjects with type 1 diabetes under a dose of 0.8 U/kg. This trial is a phase 1 single-center, randomized, double-blinded, two-treatment, two-period cross-over, 30-hour euglycaemic glucose clamp trial in subjects with type 1 diabetes mellitus. Each subject will be randomly allocated to one single dose of 0.8 U/kg of BioChaperone® Combo and to one single dose of 0.8 U/kg of Humalog® Mix 25 on two separate dosing visits.</brief_summary>
	<brief_title>A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<criteria>Type 1 diabetes mellitus for at least (or equal to ) 12 months, Treated with multiple daily insulin injections or insulin pump treatment for at least (or equal to) 12 months, Body Mass Index (BMI): 18.028.0kg/m2 (both inclusive) Type 2 diabetes mellitus, The receipt of any investigational product within 3 month prior to first dosing, Clinically significant abnormalities, as judged by the investigator, Any systemic treatment with drugs known to interfere with glucose metabolism, History of alcoholism or drug/chemical abuse and any tobacco product within 5 years prior to screening Blood or plasma donation in the past month or more than 500mL within 3 months prior to screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>